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In the mouse the H-2 complex is divided into a  number of regions consisting of K, I, 
S,  G,  and D,  (1).  Of these,  the I  region has  proven to be of particular  interest  as  it 
contains  genes  which  effect  a  number  of diverse  biological phenomena.  Included  in 
these  are  the  histocompatibility  (H)I  region  genes  and  it  has  been  of interest  to 
compare the different K, I, and D  (H) genes. Each of these regions contain one or more 
genes  which  code  for  strong  histocompatibility  effects  (H-2K  and  H-2I),  or  weaker 
effects (H-2D, H-2IC) (2,  3).  Comparisons of the serologically detected H-2K and H-2D 
specificities with the I  region Ia specificities have demonstrated these specificities to be 
clearly different, not only in their tissue distribution and function (1),  but particularly 
with regard to the production of enhancement with antiserum.  As shown initially by 
absorption  (4) and more recently, with the appropriate strain combinations (5,  6), anti- 
Ia sera can lead to skin graft enhancement for both K  and I  region differences, whereas 
anti-H-2K sera, lacking an Ia component, does not do so. These results therefore led to 
the quesiton of whether anti-H-2K or D  sera, under appropriate conditions (7,  8),  were 
graft destructive,  and  indeed,  as  shown  herein,  this  is the case,  whereas anti-Ia sera 
were shown not to be so. 
Materials and Methods 
Mice.  The mice used are listed in the Tables. BALB/C-nu/nu  mice were obtained from Dr. 
M. Holmes, Walter & Eliza Hall Institute, Melbourne and CBA/H-nu/nu  from Dr.  J. B. Smith, 
John Curtin School of Medical Research, Australian National University, Canberra. 
Antisera  and  Serology.  Alloantisera  and  anti-lymphocyte  sera  (ALS)  were  produced  as 
previously described (7,  9) and were tested in a two stage cytotoxic assay  (9). The alloantisera 
were raised to detect either H-2K, D, or Ia specificities (Tables I and II, footnotes).  Alternatively, 
sera were made K, D,  or I region specific by absorbing with either normal lymphoid cells (see 
Tables)  or with tumor cells: EL4 (an H-2  b leukemia which is H-2K  ÷, H-2D +, Iab-) or MOPC-315 
(an H-2  d plasmacytoma which is H-2K +, H-2D +, Iad+). In each case the tissues were obtained as a 
cell suspension,  washed  twice in  medium,  and  used  to  absorb  antisera,  (1  vol of cells:  3 vol 
antisera at a dilution of 1:2) for 30 rain at 4°C and 30 min at room temperature. Rabbit serum as 
an in vivo source of complement was obtained by bleeding rabbits on the day of the study and the 
sera rapidly separated and used. 
Protocol for  Studying  Antibody-Mediated  Graft Rejection in  Vivo.  The  design  of these 
experiments was based on the observation that in mice whose cellular immune mechanisms are 
suppressed, antibody-mediated graft destruction can be observed provided that a potent source of 
complement is used (7, 8). In the mice suppressed with ALS, skin grafts were performed and the 
recipients received 0.25 ml of ALS on days 1, 2, and 4 with respect to grafting. As expected, these 
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TABLE  I 
Antibody-Mediated Graft Destruction Experiments in Mice Suppressed with ALS 
Time from serum in- 
Antiserum + RC  Specificity detected  Survival time of graft  jection to rejection 
days  days 
(a) BIO.A(SR) Donor* 
1.  - 
2.  RC 
3.  AS630  H-2K  b, Ia  b 
4.  A8630 + RC  H-2K  b, Iab 
5.  AS630 absorbed EL4 + RC  Ia.9 
6.  AS630 absorbed 
B10.S(gR)  +  EC  H-2K  ~ 
(b) BIOA(2R) Donor 
7. AS630 + RC  H-21~ 
S. RC 
>35 x  6 
>35 x  6  >25 
>35 x  6  >25 
11, 11, 12, 11, 13 
>35 × 1~  2-3 
>35 x  6  >25 
11, 11, 13, 13  2-4 (×4) 
>35 x  2~  >25(x2) 
11, 11, 12  2-3 (x3) 
>35 x  25  >25(x2) 
>35 × 4  >25 
* In all experiments (B10.D2 x A)F1 male mice were suppressed with ALS 0.25 ml on days 0, 2, and 4. Groups of four to six mice 
received a skin graft on day 0 and day 9, a]loanti~rum and RC (see text). The alloantiserum (AS630)  was made as (B10.D2 x A(F~ 
anti-C57BL/6  and reacted with K  b,  P,  and D  b specificities:  (C57BL/6 spleen; titer  1/4,000); I~ and D  b (EIA:  1/4,{)00); 189 
((B10.S(gR):  1/128); Kbl  b  (B10.A(5R):  1/2,500); H.21T  (B10.A(2R):  1/128); H-2K  b  (serum  aitec absorbing with  B10.S(9R): 
B10.A(SR): 1/2,000). 
* These grsits showed early changes of rejection but subsequently recovered. 
grafts were  capable  of prolonged  survival  (>35 days)  (Table I). At day  10 after grafting,  the  ALS- 
treated  mice  (Table I) or nude  mice  (Table II) received  0.5 ml of alloantibody  and  0.25 ml of fresh 
rabbit  serum  (as a  source of complement)  intravenously,  and  shortly  thereafter,  0.5 ml of each by 
the  intraperitoneal  route.  Grafts  were  then  observed  twice daily for evidence  of rejection. 
Results 
The models chosen for studying the effects of graft rejection due to antibody 
and rabbit complement (RC),  in the absence of cellular immunity, appeared to 
be  satisfactory,  as  neither ALS treated,  nor nude mice rejected their grafts 
within the period of observation (25-35 days) (Table I, group 1; Table II groups 
1,  7,  and  12). Presumably the  nude  mice would  have  retained their  grafts 
permanently, whereas the ALS-treated mice eventually rejected their grafts. 
Suppressed  mice  given  fresh  rabbit  serum  as  a  source  of complement also 
retained their grafts  (Table I,  groups 2 and 8,  Table II,  2,  8,  13,  and 20). In 
addition, in a limited experiment (Table I, group 3) alloantibody alone did not 
cause graft rejection. Mice treated with antiserum plus RC were able to reject 
their grafts (Table I, groups 4, and 7, Table II, groups 3, 9,  10, 14, 15, 17, and 
18) in acute fashion, i.e. within 2-5 days of receiving antiserum and comple- 
ment.  All  mice thus  treated  showed evidence of graft  rejection but  several 
grafts recovered and avoided total destruction (Table I, groups 6 and 7, Table 
II, group 18). The results and the ,observations on the mode of graft rejection 
described herein conform entirely to the original descriptions of this phenomena 
(7, 8). Attempts to dissect the phenomena of antibody-mediated graft rejection 
in terms of the specificity of the antisera were then made. Most of the antisera 
used contained antibodies to H-2K or H-2D alloantigens and in addition, one or 
more known  Ia  specificities.  Sera  were therefore made  specifically reactive 
with  either H-2K,  H-2D,  or with  Ia  specificities either by absorption  or by 
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TABLE II 
Antibody-Mediated Graft Destruction  in BALB/c and CBA-nu/nu Mice Receiving 
Different Skin Grafts 
Time from serum 
Antiserum  +  RC*  Antiserum number  Survival time of grafts  injection to rejection 
days  days 
(a) BIO.A(5R)  Donor,  BALB/c.nude  recipi- 
ent 
1.  --  -  >33  -- 
2.  RC  -  >33  >23 
3.  H-2K  b, IW +  RC  AS630  11  ×  6  2 
4.  Ia.3 +  RC  AS608  >33  x  6  >23 
5.  H-2K  b, lab +  RC  AS306  11  x  4, 12 x  2  2-3 
6.  Iab (Ia.3) +  RC  AS306  absorbed  EIA  >33  x  6  >23 
(b) CBA Donor, BALB/c.nude recipient 
7.  -  -  >25  - 
8.  RC  -  >25  >15 
9.  H-2IT  +  RC  AS292  12, 12, 13, 14 
>25  x  2  3-5 
10.  H-2I~, Ia  ~  +  RC  D23  12, 12, 13, 13 
>25  x  1  3-4 
11.  Ia  ~  +  RC  AS608  >25  >15 
(c) C57BL/6  Donor,  BALB/c-nude  recipient 
12.  -  -  >25  - 
13.  RC  -  >25  >15 
14.  H-2K  b, la  b, H-2IT + RC  AS630  Ii x 5 
>25  2 
15.  H-2K  b, H-2IT +  RC  AS630 absorbed  11  x  6  2 
B10.S(9R) 
16.  Ia  b (Ia.9) +  RC  AS630 absorbed  >25  >15 
EIA 
17.  H-2K  b, It, H-21~ +  RC  AS630 absorbed  11  x  5  2 
MOPC-315 
(d) C57BL/6 Donor,  CBA-nude recipient 
18.  H-2D  b +  RC  AS303  12, 12, 13, 14  3,  3,  4, 5 
35 x  25  25 x  25 
19.  IW (la.8) +  RC  AS742  >35  ×  6  >25  ×  6 
20.  RC  -  >35  >25 
* Groups of five to six  male  nude  mice  were  used as recipients.  Sera were produced  as (a) AS630-soe Table I.  (b) AS306 (anti- 
Kbl  b) (B10.D2 ×  A)F, anti-B10.A(5R): activity (Kbit) C57BL/6 and B10.A(5R): 1/1,000; (Kb): EL4: 1/500; (1~): B10.S(gR): 1/32; (c) 
AS306 absorbing EL4 (anti-I  t  =  Ia.9): B10.A(SR): 1/64.  (d) AS608: A.TH anti-A.TL: B10.A(SR) (Ia.3, 7, 15): 1/256, CBA(Iak): 1/ 
2,000.  (e) AS292  (IT) (C3H.SW  x  B10.A(2R))F,  anti-C3H  1/600 on  CBA spleen.  (f) D23 (K~P)  (C57BL/10  x  LP.RIII)F~  anti- 
B10.A(2R): 1/5@0 on CBA spleen.  (g) AS303 (IT) (B10.D2 x  A)F, anti-B10.A(2R): 1/400 on C57BL/6. (h) AS742: (Ia.8) (B10.A × 
A)F, anti-B10.D2:1/128 on C57BL/6. 
$ See Table I. 
The  use  of such  specific  antiserum  clearly  pointed  to  the  :graft  destructive 
effects of anti-H-2K and H-2D antisera,  and the lack of such effects with anti° 
Ia  antisera.  For  example,  graft  destruction  was  produced  by AS630  +  RC 
(Table I, group 4) containing  anti-H-2K b and Ia specificities.  When the H-2K 
activity was removed by absorbing with EL4 (Table I, group 5), the destructive 
capacity of the antiserum was lost, whereas after removal of the Ia antibody by 
absorption  with  B10.S(9R)  (Table  I,  group  6),  the  antiserum  was  still  fully 
destructive.  A  similar  but  weaker  reaction  was  obtained  with  this  serum 
against the H-2D  b specificities (Table I, groups 7 and 8), i.e. in this combination, 
in ALS-suppressed mice, anti-H-2K or H-2D antibodies were destructive, anti- 
Ia antibodies were not.  It should be noted that the absorption with EIA tumor 
was specific for the H-2K, and D  specificities under study, as absorption with 
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serum. Further examples of the differential effects of H-2K, D, and Ia antisera 
were shown in Table II with athymic (nude) recipients. In these studies,  anti- 
H-2K  b (Table II, groups 3, 5, 14, 15, and 17), anti-H2K  k (Table II, group 10) and 
anti-H2D  k (Table II, groups 9 and 18) were destructive whether Ia specificities 
were present or not.  By contrast anti-Ia  b (Ia.3,  8, 9) or anti-Ia  k (Ia.1,  2,  3,  19, 
22)  (Table II,  groups 6,  11,  16,  and  19) antisera had no effect, acutely, on the 
fate of the grafts.  One problem encountered with the  H-2  b reagents  could be 
the low titer of anti-Ia.9 in the serum,  i.e.  it could be argued that the lack of 
destructive effect of anti-Ia was due to too little antibody. This possibility was 
considered to be unlikely in  view of the  inability  of anti-Ia  k sera,  (Table II, 
group  11)  with a  cytotoxic titer 1/2,000,  to cause graft destruction when used 
alone. Clearly, H-2K and H-2D antibodies can destroy grafts, anti-Ia antibodies 
cannot do so. 
Discussion 
The in vivo reactions of anti-H-2 sera can now be regarded as being complex 
and made up of the different reactions of antisera to the different components, 
i.e.  anti-H-2K,  D,  and  anti-Ia.  These  different  reactions  were  most  clearly 
observed in studies of passive enhancement wherein anti-H-2 sera with the Ia 
reaction removed by absorption were unable to enhance,  whereas those with 
anti-Ia  serum  retained,  e.g.  after absorption  with erythrocytes or with  EL4, 
could still produce enhancement  (4) but not destruction  (4,  10).  Using special 
combinations,  we  were  able  to  confirm these  findings  and  demonstrate  that 
anti-Ia antisera could suppress or delay graft rejection not only with I  region 
antigenic differences, but also with K/D differences (5, 6) and it is not unlikely 
that anti-Ia antiserum delays induction of immunity by removal of Ia antigens 
which appear to selectively stimulate helper T  cells (11). 
It should be noted that these observations on enhancement apply, not only for skin 
grafts in  mice,  but  also  for other tissues  in  other species  (4),  and this  may include 
studies in monkeys (12) and man (13-16). Why there are differences in the susceptibility 
of grafts to destruction by anti-Ia antibodies  +  RC and anti-H-2K/D antibodies is not 
clear. Anti-Ia antibody could conceivably fail to cause graft rejection for the following 
reasons: (a) absence or low density of Ia antigens on skin tissues; (b) rapid turnover of 
antigens;  (c)  immunoglobulin  class  of anti-Ia  antibodies  leading  to  poor fixing  of 
complement; or (d) failure of antibody to reach the graft. The question of the presence of 
Ia antigens in epidermal and endothelial cells, and their density, has not been finally 
settled, but Ia antigens have been directly demonstrated on epithelial cells, by cytotox- 
icity (17), so that, presumably the density of receptors is such that complement can be 
fixed - at least in vitro (17). In addition, anti-Ia antibodies of high titer are formed after 
skin grafting, indicating the presence of Ia antigens within the graft (2, 6). Ia antigens 
could conceivably have a very rapid in vivo turnover and generate complexes so rapidly 
that insufficient antibody of this specificity remains fixed to the cell surface to cause 
lysis.  This is  a  possibility,  especially in  view of our findings  on the  secretion of Ia 
antigens into the serum by stimulated lymphocytes (18), but in the absence of direct 
measurement  of secretion  rates  this  possibility  must  remain  theoretical.  It  is  also 
unlikely that noncomplement fixing antibody blocks or inhibits graft destruction as this 
is not observed in vitro. However, there may be technical problems in antibody reaching 
the graft, including the immunoglobulin class of the antibody. Also, if Ia specificities 
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could lead to the in vivo absorption of antibody by the host,  so that little or none is 
available to bind directly to the graft.  At present, none of these explanations would 
appear to be acceptable in the absence of any experimental data and the observations, 
although  valid,  remain  unexplained.  However,  whatever  the  mode  of action  of Ia 
antisera in prolonging (i.e. enhancing) skin grafts rather than leading to their destruc- 
tion, as do anti-H-2K/D antisera, the observations could be considered to be of practical 
importance for tissue allografting in man. The HLA-A, B  loci are considered to have a 
homology with the H-2K,  D  loci  in  the  mouse.  In  man,  antisera  to HLA-A  and B 
specificities  lead  to  rapid,  "hyperacute" rejection  of renal  allogral~s,  marrow,  and 
platelet grafts (16, 20). It is now apparent that the recently described B-cell alloantisera 
in  man  which  map  to  the HLA-A  and D  loci  and  which  appear  to  be  completely 
analogous to the Ia system in the mouse, are nondestructive for renal allografts (13-15). 
If this is so, then the homology may extend further, and these antibodies could be the 
specific antibodies required to produce allograft enhancement in man. 
Summary 
Nude  (athymic)  or  anti-lymphocyte  serum-treated  mice  have  absent  or 
delayed graft  rejection due  to  impaired  T-cell responses.  Nonetheless,  these 
mice can reject skin grafts,  acutely, when treated with anti-H-2 antibody and 
additional  complement.  Resolution of the components in the H-2 antisera,  by 
either absorption or by selective production of antisera of restricted specificity, 
has demonstrated that anti-H-2K or H-2D antisera  are graft destructive,  and 
as  shown  elsewhere,  are  nonenhancing.  By  contrast,  anti-Ia  sera  are  not 
capable  of causing  allograft  destruction  even  when  used  in  extremely high 
doses  and  were  previously  noted  to  be  enhancing.  The  mechanism  of such 
differential effects is not apparent, but the findings are clearly of importance to 
transplantation in man, where sera reacting specifically with B  cells may also 
be enhancing and nondestructive. 
Received for publication 7 July 1977. 
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